Ceftazidime-avibactam induced renal disorders: past and present

Ceftazidime-avibactam induced renal disorders: past and present

With the increasing prevalence of multidrug-resistant Gram-negative bacterial pathogens worldwide, antimicrobial resistance has become a significant public health concern. Ceftazidime-avibactam (CAZ-AVI) exhibited excellent in vitro activity against many carbapenemase-producing pathogens, and was wi...

Full description

Bibliographic Details
Main Authors:	Yanrong Shi, Jichao Wu, Wei Mi, Xusheng Zhang, Xiuli Ren, Chengwu Shen, Cuicui Lu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Pharmacology
Subjects:	ceftazidime-avibactam acute kidney injury clinical trials real-world studies pharmacokinetic/pharmacodynamic
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1329307/full

Similar Items

Adequacy of the Dosing and Infusion Time of Ceftazidime/Avibactam for the Treatment of Gram-Negative Bacterial Infections: A PK/PD Simulation Study
by: Han Y, et al.
Published: (2024-07-01)

A descriptive pharmacokinetic/pharmacodynamic analysis of ceftazidime‐avibactam in a case series of critically ill patients with augmented renal clearance
by: Ying Xu, et al.
Published: (2024-02-01)

The <i>Klebsiella pneumoniae</i> carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam
by: Sona Garsevanyan, et al.
Published: (2023-12-01)

In vitro effectiveness of ceftazidime-avibactam in combination with aztreonam on carbapenemase-producing Enterobacterales
by: Papa-Ezdra Romina, et al.
Published: (2023-12-01)

The Impact Of Ceftazidime-Avibactam Utilization In Hospital Setting
by: Shobana Selvaganesan, et al.
Published: (2024-12-01)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
by: Zeyu Huang, et al.
Published: (2023-11-01)

Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern Brazil
by: Natália Kehl Moreira, et al.
Published: (2023-11-01)

Safety and Efficacy of Ceftazidime/Avibactam in the Treatment of Severe Neonatal Infections
by: Mi Zhou, et al.
Published: (2024-12-01)

In vitro activity of ceftazidime/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany
by: Michael Kresken, et al.
Published: (2021-06-01)

In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula
by: Ágnes Sonnevend, et al.
Published: (2020-10-01)

A Multicenter Retrospective Study on Real-World Outcomes of ceftazidime-avibactam in gram-negative bacterial infection in Taiwan
by: Tsung Ying Zegma Yang, et al.
Published: (2024-12-01)

Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro
by: Qiuxia Lin, et al.
Published: (2021-02-01)

A Selective Medium for Screening Ceftazidime/Avibactam Resistance in Carbapenem-Resistant Enterobacterales
by: Weiliang Zeng, et al.
Published: (2022-07-01)

Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective, Single Center Study
by: Yu CH, et al.
Published: (2024-12-01)

Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China
by: Sun S, et al.
Published: (2022-04-01)

Clinical Outcomes of Ceftazidime–Avibactam versus Ceftolozane–Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy
by: Wasim S. El Nekidy, et al.
Published: (2024-07-01)

Cost-effectiveness analysis of ceftazidime avibactam versus colistin in carbapenem-resistant enterobacteriaceae in Iran
by: Zahra Goudarzi, et al.
Published: (2023-07-01)

Efficacy of Ceftazidime-Avibactam in the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection After Kidney Transplantation
by: Zhang F, et al.
Published: (2021-12-01)

Use of Ceftazidime-Avibactam in Children Admitted to Pediatric Intensive Care Units
by: André Ricardo Araujo da Silva, et al.
Published: (2024-05-01)

Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae
by: Jie Gu, et al.
Published: (2021-09-01)

Use of Ceftazidime-Avibactam for Suspected or Confirmed Carbapenem-Resistant Organisms in Children: A Retrospective Study
by: Meng H, et al.
Published: (2023-09-01)

Resistance to ceftazidime–avibactam and underlying mechanisms
by: Yuhang Wang, et al.
Published: (2020-09-01)

In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates
by: Dan Li, et al.
Published: (2023-12-01)

Identification of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam from ST11 Carbapenem-Resistant Klebsiella pneumoniae Strains
by: Yuchen Wu, et al.
Published: (2022-04-01)

Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
by: Alessandro Mancuso, et al.
Published: (2023-08-01)

Effectiveness of ceftazidime–avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia
by: Hakeam A. Hakeam, et al.
Published: (2021-08-01)

Efficacy and Safety of Ceftazidime–Avibactam Alone versus Ceftazidime–Avibactam Plus Fosfomycin for the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: A Multicentric Retrospective Study from the SUSANA Cohort
by: Marco Fois, et al.
Published: (2024-07-01)

Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China
by: Yixin Kang, et al.
Published: (2021-12-01)

In Vitro Activities of Ceftazidime–Avibactam and Aztreonam–Avibactam at Different Inoculum Sizes of Extended-Spectrum β-Lactam-Resistant Enterobacterales Blood Isolates
by: Moonsuk Bae, et al.
Published: (2021-12-01)

Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study
by: Maria Di Pietrantonio, et al.
Published: (2022-02-01)

Experience in Ceftazidime-Avibactam for treatment of MDR BGN infection in Oncologic Children
by: Wilson Toyohiro Hoshino, et al.
Published: (2025-03-01)

Analysis of the clinical application of ceftazidime-avibactam in China
by: Qing Wang, et al.
Published: (2022-04-01)

In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019
by: Zou C, et al.
Published: (2020-10-01)

In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant <i>Enterobacterales</i> Isolates from South Korea
by: Taeeun Kim, et al.
Published: (2020-12-01)

Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China
by: Xiaoyan Cui, et al.
Published: (2020-06-01)

In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam
by: Wantin Sribenjalux, et al.
Published: (2022-03-01)

Ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae accompanied hypermucoviscosity acquisition
by: Yingyi Guo, et al.
Published: (2024-10-01)

Ceftazidime–Avibactam Improves Outcomes in High-Risk Neutropenic Patients with <i>Klebsiella pneumoniae</i> Carbapenemase-Producing Enterobacterales Bacteremia
by: Fabián Herrera, et al.
Published: (2024-01-01)

Molecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime-avibactam resistance in blaKPC-3-harboring Klebsiella pneumoniae
by: Venditti C, et al.
Published: (2019-07-01)

Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i>
by: Karoline Knudsen List, et al.
Published: (2022-09-01)